We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | 장 마감 후 (AMC) | — | — | — | — | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.55 | — | — | $0 | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-1.85 | — | — | $0 |
Consensus PT $4 · 1 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 16. | HC Wainwright & Co. | — | 투자의견 하향 | Buy → Neutral | — | HC Wainwright & Co.: Buy → Neutral |
| 2026. 01. 22. | Brookline Capital | — | 투자의견 하향 | Buy → Hold | — | Brookline Capital: Buy → Hold |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-1.26 | — | — | $0 | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Stored first · Google News · Yahoo Finance (English)
Lisata Therapeutics (LSTA) Files 8-K on Proposed Acquisition and Tender Offer – Key Information for NASDAQ Investors - Minichart
Lisata Therapeutics (LSTA) Files 8-K on Proposed Acquisition and Tender Offer – Key Information for NASDAQ Investors Minichart
Kuva to seek Lisata tender offer (LSTA) under March 6, 2026 merger - Stock Titan
Kuva to seek Lisata tender offer (LSTA) under March 6, 2026 merger Stock Titan
Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing - Investing.com UK
Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing Investing.com UK
Lisata Therapeutics Faces Uncertainty in Kuva Tender Offer - TipRanks
Lisata Therapeutics Faces Uncertainty in Kuva Tender Offer TipRanks
Tender offer for Lisata Therapeutics (LSTA) delayed as Kuva Labs reevaluates timing - Stock Titan
Tender offer for Lisata Therapeutics (LSTA) delayed as Kuva Labs reevaluates timing Stock Titan
Lisata Therapeutics Announces Amendment to Merger Agreement with Kuva Labs and Contingent Value Rights Agreement - Minichart
Lisata Therapeutics Announces Amendment to Merger Agreement with Kuva Labs and Contingent Value Rights Agreement Minichart